Further evidence for association of YKL-40 with severe asthma airway remodeling.


Journal

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
ISSN: 1534-4436
Titre abrégé: Ann Allergy Asthma Immunol
Pays: United States
ID NLM: 9503580

Informations de publication

Date de publication:
06 2022
Historique:
received: 12 12 2021
revised: 25 02 2022
accepted: 16 03 2022
pubmed: 29 3 2022
medline: 31 5 2022
entrez: 28 3 2022
Statut: ppublish

Résumé

The chitinase-like protein YKL-40 is associated with airflow limitation on spirometry and airway remodeling in patients with asthma. It remains unclear whether YKL-40 is associated with morphologic changes in the airways and parenchyma or with future progression of airflow limitation in severe asthma. To evaluate the association of circulating YKL-40 levels with morphologic changes in the airways and parenchyma and with longitudinal progression of airflow limitation. The patients were participants in the Hokkaido Severe Asthma Cohort Study (n = 127), including smokers. This study consisted of 2 parts. In analysis 1, we analyzed associations between circulating YKL-40 levels and several asthma-related indices, including computed tomography-derived indices of proximal wall area percentage, the complexity of the airways (airway fractal dimension), and the parenchyma (exponent D) cross-sectionally (n = 97). In analysis 2, we evaluated the impact of circulating YKL-40 levels on forced expiratory volume in 1 second (FEV Circulating YKL-40 levels were significantly associated with proximal wall area percentage and airway fractal dimension (r = 0.25, P = .01; r = -0.22, P = .04, respectively), but not with exponent D. The mean annual change in FEV These results provide further evidence for the association of YKL-40 with the pathogenesis of airway remodeling in severe asthma.

Sections du résumé

BACKGROUND
The chitinase-like protein YKL-40 is associated with airflow limitation on spirometry and airway remodeling in patients with asthma. It remains unclear whether YKL-40 is associated with morphologic changes in the airways and parenchyma or with future progression of airflow limitation in severe asthma.
OBJECTIVE
To evaluate the association of circulating YKL-40 levels with morphologic changes in the airways and parenchyma and with longitudinal progression of airflow limitation.
METHODS
The patients were participants in the Hokkaido Severe Asthma Cohort Study (n = 127), including smokers. This study consisted of 2 parts. In analysis 1, we analyzed associations between circulating YKL-40 levels and several asthma-related indices, including computed tomography-derived indices of proximal wall area percentage, the complexity of the airways (airway fractal dimension), and the parenchyma (exponent D) cross-sectionally (n = 97). In analysis 2, we evaluated the impact of circulating YKL-40 levels on forced expiratory volume in 1 second (FEV
RESULTS
Circulating YKL-40 levels were significantly associated with proximal wall area percentage and airway fractal dimension (r = 0.25, P = .01; r = -0.22, P = .04, respectively), but not with exponent D. The mean annual change in FEV
CONCLUSION
These results provide further evidence for the association of YKL-40 with the pathogenesis of airway remodeling in severe asthma.

Identifiants

pubmed: 35342020
pii: S1081-1206(22)00207-1
doi: 10.1016/j.anai.2022.03.016
pii:
doi:

Substances chimiques

Adipokines 0
CHI3L1 protein, human 0
Chitinase-3-Like Protein 1 0
Lectins 0

Banques de données

UMIN-CTR
['R000003917']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

682-688.e5

Informations de copyright

Copyright © 2022 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Auteurs

Hirokazu Kimura (H)

Faculty of Medicine, Department of Respiratory Medicine, Hokkaido University, Sapporo, Japan. Electronic address: hikimura@pop.med.hokudai.ac.jp.

Kaoruko Shimizu (K)

Faculty of Medicine, Department of Respiratory Medicine, Hokkaido University, Sapporo, Japan.

Naoya Tanabe (N)

Graduate School of Medicine, Department of Respiratory Medicine, Kyoto University, Kyoto, Japan.

Hironi Makita (H)

Faculty of Medicine, Department of Respiratory Medicine, Hokkaido University, Sapporo, Japan.

Natsuko Taniguchi (N)

Faculty of Medicine, Department of Respiratory Medicine, Hokkaido University, Sapporo, Japan.

Hiroki Kimura (H)

Faculty of Medicine, Department of Respiratory Medicine, Hokkaido University, Sapporo, Japan.

Masaru Suzuki (M)

Faculty of Medicine, Department of Respiratory Medicine, Hokkaido University, Sapporo, Japan.

Yuki Abe (Y)

Faculty of Medicine, Department of Respiratory Medicine, Hokkaido University, Sapporo, Japan.

Machiko Matsumoto-Sasaki (M)

Faculty of Medicine, Department of Respiratory Medicine, Hokkaido University, Sapporo, Japan.

Akira Oguma (A)

Faculty of Medicine, Department of Respiratory Medicine, Hokkaido University, Sapporo, Japan.

Michiko Takimoto-Sato (M)

Faculty of Medicine, Department of Respiratory Medicine, Hokkaido University, Sapporo, Japan.

Nozomu Takei (N)

Faculty of Medicine, Department of Respiratory Medicine, Hokkaido University, Sapporo, Japan.

Munehiro Matsumoto (M)

Faculty of Medicine, Department of Respiratory Medicine, Hokkaido University, Sapporo, Japan.

Houman Goudarzi (H)

Faculty of Medicine, Department of Respiratory Medicine, Hokkaido University, Sapporo, Japan.

Susumu Sato (S)

Graduate School of Medicine, Department of Respiratory Medicine, Kyoto University, Kyoto, Japan.

Junya Ono (J)

R&D Center, Shino-Test Corporation, Kanagawa, Japan.

Kenji Izuhara (K)

Division of Medical Biochemistry, Department of Biomolecular Sciences, Saga Medical School, Saga, Japan.

Toyohiro Hirai (T)

Graduate School of Medicine, Department of Respiratory Medicine, Kyoto University, Kyoto, Japan.

Masaharu Nishimura (M)

Faculty of Medicine, Department of Respiratory Medicine, Hokkaido University, Sapporo, Japan; Hokkaido Medical Research Institute for Respiratory Diseases, Sapporo, Japan.

Satoshi Konno (S)

Faculty of Medicine, Department of Respiratory Medicine, Hokkaido University, Sapporo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH